Skip to content
6-K

Foreign Interim / Material

INTELLIPHARMACEUTICS INTERNATIONAL INC.

0001654954-22-009947

← back to feed
Filed
Jul 21, 2022 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Cash And Equivalents Q2 2022 · May 31, 2022 $372.8K
Cash And Equivalents Q2 2022 · Nov 30, 2021 $771.95K
Total Liabilities Q2 2022 · May 31, 2022 $11.74M
Total Liabilities Q2 2022 · Nov 30, 2021 $10.25M
Current Assets Q2 2022 · May 31, 2022 $908.29K
Current Assets Q2 2022 · Nov 30, 2021 $1.1M
Total Assets Q2 2022 · May 31, 2022 $1.88M
Total Assets Q2 2022 · Feb 28, 2022 $1.89M
Total Assets Q2 2022 · Nov 30, 2021 $2.1M
Gross Profit Q2 2022 · May 31, 2022 $0
Gross Profit Q2 2022 · May 31, 2022 $16.98K
Gross Profit Q2 2022 · May 31, 2021 $93.43K
Gross Profit Q2 2022 · May 31, 2021 $93.43K
Operating Cash Flow Q2 2022 · May 31, 2021 −$763.77K
Operating Cash Flow Q2 2022 · May 31, 2021 −$763.14K
Stockholders Equity Q2 2022 · May 31, 2021 −$5.03M
Stockholders Equity Q2 2022 · Nov 30, 2020 −$6.31M
Sga Expense Q2 2022 · May 31, 2021 $453.22K
Sga Expense Q2 2022 · May 31, 2021 $625.27K
Rd Expense Q2 2022 · May 31, 2021 $481.68K
Rd Expense Q2 2022 · May 31, 2021 $1.03M
Net Income Q2 2022 · May 31, 2021 −$1M
Net Income Q2 2022 · May 31, 2021 −$1.92M
Operating Income Q2 2022 · May 31, 2021 −$906.85K
Operating Income Q2 2022 · May 31, 2021 −$1.69M
Revenue Q2 2022 · May 31, 2021 $93.43K
Revenue Q2 2022 · May 31, 2021 $93.43K